2.33

0.34% -0.008

Xortx Therapeutics Inc (XRTX)

Überblick Nachrichten Preisverlauf Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.338

Offen:

$2.18

24-Stunden-Volumen:

5,223

Relative Volume:

0.33

Marktkapitalisierung:

$4.21M

Einnahmen:

Nettoeinkommen (Verlust:

$-2.77M

KGV:

-0.8804

EPS:

-2.6464

Netto-Cashflow:

$-2.69M

1W Leistung:

+3.10%

1M Leistung:

+9.91%

6M Leistung:

+13.66%

1J Leistung:

-42.07%

1-Tages-Spanne:

$2.18

$2.34

1-Wochen-Bereich:

$2.16

$2.64

52-Wochen-Spanne:

$1.725

$7.05

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Firmenname

Xortx Therapeutics Inc

Sektor

Healthcare (1083)

Branche

Biotechnology (602)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

XRTX's Discussions on Twitter

Compare XRTX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XRTX Xortx Therapeutics Inc	2.32	3.67M	0	-2.77M	-2.69M	-2.6464
VRTX Vertex Pharmaceuticals Inc	549.01	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	812.01	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,031.59	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.62	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	204.91	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten

Aug 17, 2026

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks

Aug 17, 2026

Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan

Aug 17, 2026

Aug 15, 2026

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 15, 2026

Aug 13, 2026

XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn

Aug 13, 2026

Aug 12, 2026

XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn

Aug 12, 2026

Aug 05, 2026

XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail

Aug 05, 2026

XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionModified Schiff - vinanet.vn

Aug 05, 2026

Aug 04, 2026

Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan

Aug 04, 2026

Aug 02, 2026

XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fibonacci Retracement - dars.gov.et

Aug 02, 2026

Aug 01, 2026

XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et

Aug 01, 2026

Jul 31, 2026

XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com

Jul 31, 2026

XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan

Jul 31, 2026

Jul 29, 2026

XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks

Jul 29, 2026

XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan

Jul 29, 2026

XORTX Appoints New Director - GlobeNewswire

Jul 29, 2026

XORTX Board Gains Director With Over 20 Years in Financial Services - Stock Titan

Jul 29, 2026

Jul 28, 2026

XORTX Therapeutics, Inc. Revenue Breakdown – TSXV:XRTX - TradingView

Jul 28, 2026

Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine

Jul 28, 2026

Jul 27, 2026

Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome

Jul 27, 2026